Regeneron Case Likely to Join Teva Pharmaceuticals’ FCA Causation Appeal

ArentFox Schiff – Given the ongoing, directly contradictory rulings from two judges in the same judicial district, as well as the current lack of a binding appellate guidance, the issue is headed to the First Circuit for a critical showdown that will have wide-ranging impact on future FCA proceedings.